BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Core Insights - BioCryst Pharmaceuticals will present five abstracts on the real-world use of ORLADEYO® (berotralstat) for hereditary angioedema (HAE) at the 2024 AAAAI annual meeting [1] - ORLADEYO is the first oral therapy specifically designed to prevent HAE attacks in patients aged 12 and older [2][3] Group 1: Abstract Presentations - The first abstract discusses how berotralstat prophylaxis reduces HAE attack rates regardless of baseline attacks [1] - The second abstract highlights consistently low HAE attack rates with berotralstat, irrespective of prior prophylaxis [1] - The third abstract presents interim analysis from the Berolife Study on the tolerability and effectiveness of berotralstat for long-term prophylaxis [1] - The fourth abstract evaluates adherence to berotralstat through a prospective survey in community pharmacies [1] - The fifth abstract assesses the real-world effectiveness of berotralstat in HAE patients with and without C1-inhibitor deficiency [1] Group 2: Product Information - ORLADEYO is indicated for the prophylaxis of HAE attacks in adults and pediatric patients aged 12 years and older [3] - The drug works by decreasing the activity of plasma kallikrein, preventing HAE attacks with a once-daily capsule [2] - Safety information indicates that the effectiveness of ORLADEYO for acute HAE attacks has not been established, and it should not be used for such treatment [4] Group 3: Safety and Efficacy - Common adverse reactions in patients receiving ORLADEYO include abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease [5] - A reduced dosage of 110 mg is recommended for patients with moderate or severe hepatic impairment [5] - The drug is a moderate inhibitor of CYP2D6 and CYP3A4, necessitating monitoring for concomitant medications [6]